PIK3CD Correlates with Prognosis, Epithelial-mesenchymal Transition and Tumor Immune Infiltration in Breast Carcinoma

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2023 Oct 20

PMID 37861728

Authors

Wenxing He

Haoyi Zhang

Hong Cheng

Jianfeng Wen

Dongmei Li

Affiliations

Soon will be listed here.

Abstract

Background: Breast carcinoma (BRCA) is one of the most common, fatal, and aggressive cancers, with increasing morbidity that has a major impact on human health. PIK3CD appears to have important roles in the beginning and advancement of various forms of human cancer, according to mounting data. However,the particular role and mechanism of PIK3CD in BRCA remains not fully identified.

Methodology: The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/ ), Genotype-Tissue Expression (GTEx) data and the UCSC Xena browser ( https://xenabrowser.net ) data were used in this study's initial pan-cancer analysis of PIK3CD expression and prognosis. Circular RNAs (circRNAs) that regulated the expression of PIK3CD were subsequently found using a combination of in silico investigations of expression, correlation, and survival. Measurements of PIK3CD expression and an analysis of the in vitro function of PIK3CD in BRCA cells were performed using real-time RT-PCR, Western blotting and Transwell assays.

Results: In BRCA GLI2, RAB32, LAMB1, MGAT2, ITGA8, CHF, COL6A3 and PRRX1-miR-30b-5p axis was identified as the most likely upstream CircRNA-related route of PIK3CD. PIK3CD was correlated with the expression of EMT markers. The PIK3CD cDNA improved the capacity for invasion and migration. The expression of PIK3CD was linked to some of the m1A/m5C/m6A regulators. Additionally, it was discovered that the expression of PIK3CD was found to be highly connected to the expression of immunological checkpoints, immune cell biomarkers, and tumor immune cell invasion.

Conclusions: Our findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.

Citing Articles

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.

Multifaceted bioinformatic analysis of m6A-related ferroptosis and its link with gene signatures and tumour-infiltrating immune cells in gliomas.

Yang Y, Hao L, Guiyang L, Haozhe P J Cell Mol Med. 2024; 28(17):e70060.

PMID: 39248438 PMC: 11382363. DOI: 10.1111/jcmm.70060.

Unveiling the Bioactive Efficacy of 'Stricta' Essential Oil: Composition, In Vitro Activities, and In Silico Analyses.

Fikry E, Orfali R, Tawfeek N, Perveen S, Ghafar S, El-Domiaty M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204124 PMC: 11357629. DOI: 10.3390/ph17081019.

TOX: a potential new immune checkpoint in cancers by pancancer analysis.

Qiu S, Lin W, Zhou Z, Hong Q, Chen S, Li J Discov Oncol. 2024; 15(1):354.

PMID: 39152366 PMC: 11329495. DOI: 10.1007/s12672-024-01236-1.

References

Voutsadakis I . The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer (Dove Med Press). 2015; 7:303-19. PMC: 4567227. DOI: 10.2147/BCTT.S71163. View

Herrera F, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M . Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2021; 12(1):108-133. PMC: 9401506. DOI: 10.1158/2159-8290.CD-21-0003. View

Zou Q, Wang X, Ren D, Hu B, Tang G, Zhang Y . DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021; 9(9). PMC: 8458312. DOI: 10.1136/jitc-2021-002671. View

Feng M, Jiang W, Kim B, Zhang C, Fu Y, Weissman I . Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019; 19(10):568-586. PMC: 7002027. DOI: 10.1038/s41568-019-0183-z. View

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R . Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nat Immunol. 2022; 23(2):262-274. DOI: 10.1038/s41590-021-01120-y. View

Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J . PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression. J Clin Invest. 2020; 130(6):3188-3204. PMC: 7260014. DOI: 10.1172/JCI128313. View

Kristen Hall M, Burch A, Schwalbe R . Functional analysis of N-acetylglucosaminyltransferase-I knockdown in 2D and 3D neuroblastoma cell cultures. PLoS One. 2021; 16(11):e0259743. PMC: 8575246. DOI: 10.1371/journal.pone.0259743. View

Chen J, Huang J, Luo B, Dong S, Wang R, Jiang Z . PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer. Cancer Sci. 2019; 110(3):997-1011. PMC: 6398891. DOI: 10.1111/cas.13931. View

Qiu H, Shen X, Chen B, Chen T, Feng G, Chen S . miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8. Apoptosis. 2021; 26(5-6):261-276. DOI: 10.1007/s10495-021-01665-1. View

10.

Cheng Y, Su Y, Wang S, Liu Y, Jin L, Wan Q . Identification of circRNA-lncRNA-miRNA-mRNA Competitive Endogenous RNA Network as Novel Prognostic Markers for Acute Myeloid Leukemia. Genes (Basel). 2020; 11(8). PMC: 7465400. DOI: 10.3390/genes11080868. View

11.

Liu Z, Wang T, She Y, Wu K, Gu S, Li L . N-methyladenosine-modified circIGF2BP3 inhibits CD8 T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021; 20(1):105. PMC: 8377850. DOI: 10.1186/s12943-021-01398-4. View

12.

Johnson R, Nguyen M, Padalecki S, Grubbs B, Merkel A, Oyajobi B . TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2010; 71(3):822-31. PMC: 3077118. DOI: 10.1158/0008-5472.CAN-10-2993. View

13.

Qi L, Zhang W, Ren X, Xu R, Yang Z, Chen R . Cross-Talk of Multiple Types of RNA Modification Regulators Uncovers the Tumor Microenvironment and Immune Infiltrates in Soft Tissue Sarcoma. Front Immunol. 2022; 13:921223. PMC: 9289169. DOI: 10.3389/fimmu.2022.921223. View

14.

Xu B, Lu M, Yan L, Ge M, Ren Y, Wang R . A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. Front Immunol. 2021; 12:796647. PMC: 8695566. DOI: 10.3389/fimmu.2021.796647. View

15.

Zhu J, Zhang X, Gao W, Hu H, Wang X, Hao D . lncRNA/circRNA‑miRNA‑mRNA ceRNA network in lumbar intervertebral disc degeneration. Mol Med Rep. 2019; 20(4):3160-3174. PMC: 6755180. DOI: 10.3892/mmr.2019.10569. View

16.

Wu J, Cheng J, Zhang F, Luo X, Zhang Z, Chen S . Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer. Ann Transl Med. 2020; 8(16):993. PMC: 7475494. DOI: 10.21037/atm-20-5220. View

17.

Stanton S, Disis M . Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016; 4:59. PMC: 5067916. DOI: 10.1186/s40425-016-0165-6. View

18.

Li D, Li K, Zhang W, Yang K, Mu D, Jiang G . The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma. Front Immunol. 2022; 13:918140. PMC: 9272990. DOI: 10.3389/fimmu.2022.918140. View

19.

Dong J, Lv Z, Chen Q, Wang X, Li F . PRRX1 drives tamoxifen therapy resistance through induction of epithelial-mesenchymal transition in MCF-7 breast cancer cells. Int J Clin Exp Pathol. 2020; 11(5):2629-2635. PMC: 6958258. View

20.

Kim R, An M, Lee H, Mehta A, Heo Y, Kim K . Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discov. 2021; 12(4):984-1001. PMC: 9387589. DOI: 10.1158/2159-8290.CD-21-0888. View